ILMN vs. INCY: Illumina vs. Incyte Stock Comparison

November 11, 2026

How do Illumina (ILMN) and Incyte (INCY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Illumina (ILMN) and Incyte (INCY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ILMN is classified in Life Sciences Tools & Services while INCY is classified in Biotechnology.

Company profile comparison for Illumina (ILMN) and Incyte (INCY)
Profile Item	ILMN	INCY
Name	Illumina Inc.	Incyte Corp.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	32.23 billion USD	24.39 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	July 28, 2000	November 4, 1993
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ILMN

INCY

GSPC

Illumina (ILMN) vs. Incyte (INCY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Illumina (ILMN) and Incyte (INCY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Illumina (ILMN) and Incyte (INCY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Illumina (ILMN) and Incyte (INCY)
Metric	ILMN	INCY
Total Return (1Y)	79.70%	14.06%
Total Return (3Y, Annualized)	28.16%	32.03%
Total Return (5Y, Annualized)	-10.65%	12.69%

Risk Profile

Drawdown History

ILMN

INCY

GSPC

Illumina (ILMN) vs. Incyte (INCY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Illumina (ILMN) and Incyte (INCY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Illumina (ILMN) and Incyte (INCY)
Metric	ILMN	INCY
Volatility (1Y, Annualized)	48.47%	33.19%
Beta (5Y)	1.46	0.78
Max Drawdown (5Y)	-82.95%	-40.50%
Avg. Volume (3M)	2.77M	1.58M

Risk-Adjusted Performance

Risk-Return Positioning

ILMN and INCY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Illumina (ILMN) and Incyte (INCY)
Metric	ILMN	INCY
Sharpe Ratio (1Y)	1.56	0.29
Sortino Ratio (1Y)	2.25	0.46

Profitability

ROE (TTM)

Both Illumina (ILMN) at 32.39% and Incyte (INCY) at 7.84% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.39%

Max: 109.18%
ILMN: 32.39%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.84%

Max: 109.18%
INCY: 7.84%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Illumina (ILMN) vs. Incyte (INCY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Illumina (ILMN) at 19.72% keeps the most of each sales dollar — above its industry’s net margin range — and Incyte (INCY) at 6.71% also retains a top-quartile share.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.72%

ILMN: 19.72%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.71%

Max: 18.05%
INCY: 6.71%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Illumina (ILMN) vs. Incyte (INCY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Illumina (ILMN) at 20.02% and Incyte (INCY) at 33.72% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max: 83.12%
ILMN: 20.02%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.72%

Max: 83.12%
INCY: 33.72%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Illumina (ILMN) vs. Incyte (INCY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Illumina (ILMN) and Incyte (INCY)
Metric	ILMN	INCY
ROE (TTM)	32.39%	7.84%
ROA (TTM)	8.32%	17.78%
Net Margin (TTM)	19.72%	6.71%
Operating Margin (TTM)	20.02%	33.72%
Gross Margin (TTM)	67.68%	56.02%

Growth

Revenue Growth

Incyte (INCY) at 21.22% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Illumina (ILMN) vs. Incyte (INCY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Incyte (INCY) reports EPS growth of 4,173.33%, ranked against its industry; Illumina (ILMN) has no EPS growth figure this period.

Illumina (ILMN) vs. Incyte (INCY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Illumina (ILMN) and Incyte (INCY)
Metric	ILMN	INCY
Revenue Growth (YoY)	-0.66%	21.22%
Revenue Growth (3Y CAGR)	-1.78%	14.84%
EPS Growth (YoY)	--	4,173.33%
EPS Growth (3Y CAGR)	--	61.56%

Financial Strength

Current Ratio (MRQ)

Both Illumina (ILMN) at 2.63 and Incyte (INCY) at 3.84 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max: 25.13
Q3: 12.13
Median: 5.52
ILMN: 2.63
Q1: 2.47
Min: 0.10

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.84

Max: 25.13
Q3: 12.13
Median: 5.52
INCY: 3.84
Q1: 2.47
Min: 0.10

Illumina (ILMN) vs. Incyte (INCY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Incyte (INCY) at 0.01 keeps leverage in the lower quartile, while Illumina (ILMN) at 0.74 sits in the higher-leverage quartile.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.74

Max: 1.42
ILMN: 0.74
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
INCY: 0.01
Min: 0.00

Illumina (ILMN) vs. Incyte (INCY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Illumina (ILMN) and Incyte (INCY)
Metric	ILMN	INCY
Current Ratio (MRQ)	2.63	3.84
Debt / Equity (MRQ)	0.74	0.01
Net Debt / EBITDA	0.85	-1.88

Dividends

Dividend Yield (TTM)

Neither Illumina (ILMN) nor Incyte (INCY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INCY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Illumina (ILMN) vs. Incyte (INCY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Illumina (ILMN) nor Incyte (INCY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INCY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Illumina (ILMN) vs. Incyte (INCY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Illumina (ILMN) and Incyte (INCY)
Metric	ILMN	INCY
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Illumina (ILMN) at 36.68 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.68

Max: 85.34
Q3: 43.46
ILMN: 36.68
Median: 26.69
Q1: 13.30
Min: 0.07

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

61.05

Max: 85.34
INCY: 61.05
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Illumina (ILMN) vs. Incyte (INCY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Illumina (ILMN) at 7.10 and Incyte (INCY) at 4.06 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.10

Max: 58.18
Q3: 25.77
Median: 7.30
ILMN: 7.10
Q1: 3.01
Min: 0.01

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.06

Max: 58.18
Q3: 25.77
Median: 7.30
INCY: 4.06
Q1: 3.01
Min: 0.01

Illumina (ILMN) vs. Incyte (INCY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Incyte (INCY) at 4.33 is valued about in line with its industry on P/B ratio, while Illumina (ILMN) at 10.30 carries an above-peer premium to book — ILMN is pricier on assets.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.30

Max: 13.53
ILMN: 10.30
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.33

Max: 13.53
Q3: 6.54
INCY: 4.33
Median: 3.25
Q1: 1.69
Min: -5.59

Illumina (ILMN) vs. Incyte (INCY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Illumina (ILMN) and Incyte (INCY)
Metric	ILMN	INCY
P/E Ratio (TTM)	36.68	61.05
P/S Ratio (TTM)	7.10	4.06
P/B Ratio (MRQ)	10.30	4.33
Free Cash Flow Yield (TTM)	2.67%	5.28%